There is also a subset of analytes which are strong in both HD and good outcome patient cells, but reduced in bad outcome patients (IFNα, IL-18, IL-1α, IL-21) all of which have type 1 skewing and antitumor immunity activity. This evidence concerns the gene IL21 and Huntington disease.